DOCSLIB.ORG

Comparative Effect of Nutraceuticals on Lipid Profile: a Protocol for Systematic Review and Network Meta-­Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Effect of Nutraceuticals on Lipid Profile: a Protocol for Systematic Review and Network Meta-­Analysis Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2019-032755 on 20 August 2020. Downloaded from Comparative effect of nutraceuticals on lipid profile: a protocol for systematic review and network meta- analysis Jakub Morze ,1 Tadeusz Osadnik,2,3 Kamila Osadnik,2 Mateusz Lejawa,2 Grzegorz Jakubiak,2 Natalia Pawlas ,2 Mariusz Gasior,4 Lukas Schwingshackl,5 Maciej Banach6,7,8 To cite: Morze J, Osadnik T, ABSTRACT Strengths and limitations of this study Osadnik K, et al. Comparative Introduction According to the common definition, effect of nutraceuticals on nutraceuticals are components found in food that can act ► This network meta- analysis will be the first to ex- lipid profile: a protocol for as therapeutic substances. Recently, the International Lipid systematic review and network plore the comparative effectiveness of different nu- Expert Panel published two position papers covering the meta- analysis. BMJ Open traceuticals on lipid profile. topic of lipid- lowering nutraceuticals and their potential 2020;10:e032755. doi:10.1136/ ► Results of our review will address the question use as a complementary treatment in addition to statins bmjopen-2019-032755 which nutraceutical is the most promising in terms or as an alternative treatment in statin- intolerant patients. of lowering plasma lipids. ► Prepublication history and The aim of this study was to compare the effect of ► Variations in trial design, base patient character- additional material for this different nutraceuticals on lipid profiles in a systematic paper are available online. To istics, doses and administration mode of nutra- review with pairwise and network meta- analyses. view these files, please visit ceuticals, which may increase heterogeneity and Methods and analysis Three databases, including the journal online (http:// dx. doi. inconsistency of networks, will be addressed by PubMed, Embase and the Cochrane Central Register org/ 10. 1136/ bmjopen- 2019- appropriate subgroup analyses. 032755). of Controlled Trials, will be searched without time or ► Different mechanisms of action of various publication language restrictions. The estimated end date nutraceuticals. Received 03 July 2019 for the searches will be 29 March 2020. Each stage of ► Low number of eligible head- to- head trials may pro- Revised 21 May 2020 the review, including the study section, data extraction, duce sparsely connected network of treatments. Accepted 03 July 2020 and risk of bias and quality of evidence assessments, will be performed in duplicate. Randomised controlled trials meeting the following criteria will be eligible for inclusion: http://bmjopen.bmj.com/ (1) participants aged ≥18 years, (2) intervention with a INTRODUCTION selected nutraceutical (artichoke, berberine, bergamot, Cardiovascular diseases (CVDs) account for soluble fibres, green tea, garlic, lupin, plant sterols and one-third of deaths and remain as the most stanols, red yeast rice, soybean, spirulina or a combination 1 of the aforementioned nutraceuticals), (3) administration common cause of mortality worldwide. of the treatment in the form of capsules, pills, powders, According to the Global Burden of Diseases, solutions, tablets or enriched food items, (4) comparison in 2015, the estimated global prevalence 2 with another nutraceutical or placebo, (5) intervention of CVD was more than 420 million cases. period ≥3 weeks and (6) lipid profile (low- density Among many modifiable risk factors, such as on September 26, 2021 by guest. Protected copyright. lipoprotein cholesterol, high- density lipoprotein cholesterol, smoking cessation, changes in dietary habits, total cholesterol, triglycerides) as an outcome. Random- weight loss, and blood pressure and glucose effect pairwise and network meta-analyses will be used control, lowering plasma cholesterol remains to summarise the relative effect of each nutraceutical a key factor in the primary prevention of in comparison to the effect of every other nutraceutical. CVD.3 Subgroup analyses will be stratified by age, sex, ethnicity, Statins remain the most widely used lipid- sample size, length of trial follow- up, baseline cholesterol 4 level and presence of other comorbidities. lowering drugs for CVD prevention. A © Author(s) (or their Ethics and dissemination This review will summarise large body of evidence from high-quality employer(s)) 2020. Re- use randomised clinical trials suggests that statin permitted under CC BY-NC. No findings from primary studies, and therefore no ethics commercial re- use. See rights approval is required. The results will be presented at therapy is effective at reducing levels of and permissions. Published by conferences as well as published in a peer- reviewed serum low- density lipoprotein cholesterol BMJ. journal. (LDL-C) and total cholesterol (TC) as well as For numbered affiliations see PROSPERO registration number CRD42019132877. the risk of cardiovascular events and deaths.5 end of article. The current American College of Cardi- Correspondence to ology/American Heart Association guide- Jakub Morze; lines recommend the inclusion of statins for jakub. morze@ uwm. edu. pl primary prevention in patients with diabetes, Morze J, et al. BMJ Open 2020;10:e032755. doi:10.1136/bmjopen-2019-032755 1 Open access BMJ Open: first published as 10.1136/bmjopen-2019-032755 on 20 August 2020. Downloaded from severe hypercholesterolemia and mild-to- moderate hyper- methods for conducting and describing the results of cholesterolemia depending on individual CVD risk.6 this review have been planned according to Preferred Despite the good general safety profile of statins, recent Reporting Items for Systematic Reviews and Meta- concerns have been raised about the prevalence of statin- Analyses (PRISMA) and its extensions dedicated to associated muscle syndrome or transient elevation of network meta- analyses.25 26 The text of the protocol was liver syndromes and other less frequent adverse effects written according to the Preferred Reporting Items for like occurrence of diabetes mellitus.7 Second- line drugs Systematic Review and Meta- Analysis Protocols guidelines like ezetimibe, although less frequently, can also cause for reporting protocols.27 muscle pain and liver enzyme elevation.8 Drugs like bile acid sequestrants or niacin are rarely used mainly due to Patient and public involvement 9 10 adverse effects leading to non- compliance. Discontin- Patients and the public were not involved in the design or uation of lipid- lowering treatment is associated with an planning of the study. increased risk of atherosclerotic CVD and mortality.11 Moreover, prescription of lipid- lowering drugs for the Eligibility criteria elderly patients in primary prevention is a subject of Studies fulfilling the eligibility criteria listed below will be debate.12 These issues have shifted efforts to identifying included in the systematic review. evidence for alternative therapies, whose use was not extensively addressed in previous guidelines. Due to lipid- lowering potential, some nutraceuticals Participants can be considered as an option in the therapy of lipid We will only include studies conducted with adults disorders. According to common definitions, nutraceuti- (subjects aged ≥18 years). Since previous meta-analyses cals are components found in food that can act as thera- indicated the vast use of nutraceuticals in patients with peutic substances.13 The potential lipid- lowering activity other metabolic disorders associated with increased of selected nutraceuticals can be explained by inhibiting CVD risk, participants will be included regardless of disease, normocholesterolemic or hypercholesterolemic liver cholesterol synthesis, decreasing cholesterol absorp- 17–23 tion and increasing cholesterol excretion, as well as influ- status. However, these conditions will provide a basis encing fatty acid metabolism.14 Additional benefits from for appropriate subgroup analyses. the use of nutraceuticals have been demonstrated on glycaemic control, blood pressure, endothelial function Interventions and comparators and subclinical inflammation.15 16 A large body of system- The literature includes data on more than 40 single and 28 atic reviews and meta- analyses reported a beneficial effect combined lipid- lowering nutraceuticals. Since LDL- C 3 of different nutraceuticals on plasma LDL-C, high-density is a primary lipid target in CVD prevention, the scope lipoprotein cholesterol (HDL-C), triglycerides (TG) and of this review will be limited to nutraceuticals with the http://bmjopen.bmj.com/ TC.17–23 However, the vast majority of these reviews did potential to lower LDL-C. To identify eligible agents, not report the quality of the summarised evidence, which we carefully evaluated recent position papers on nutra- is a key issue to address the confidence in the obtained ceuticals from the International Lipid Expert Panel and 14 24 results and inform clinical guidelines. related meta- analyses. The following interventions The International Lipid Expert Panel has published will be considered for inclusion: two position papers covering the topic of lipid- lowering ► Artichoke—extracts from Cynara scolymus and C. nutraceuticals and their potential use as a complementary cardunculus. treatment to statins or an alternative therapy for patients ► Berberine—isoquinoline alkaloids isolated from on September 26, 2021 by guest. Protected copyright. with statin intolerance.24 Since both reports described the barberry (Berberis vulgaris), tree turmeric (B. aristata),
Load more

Recommended publications
  • Effects of a Policosanol Supplement on Serum Lipid Concentrations In
    Downloaded from https://www.cambridge.org/core British Journal of Nutrition (2006), 95, 968–975 DOI: 10.1079/BJN20061715 q The Authors 2006 Effects of a policosanol supplement on serum lipid concentrations in . IP address: hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects 170.106.40.139 A. Greyling, C. De Witt, W. Oosthuizen and J. C. Jerling* , on School of Physiology, Nutrition and Consumer Sciences, North-West University (Potchefstroom Campus), South Africa 25 Sep 2021 at 08:49:47 (Received 28 June 2005 – Revised 28 November 2005 – Accepted 2 December 2005) Policosanol is a mixture of higher aliphatic primary alcohols that is extracted from purified sugar cane wax or a variety of other plant sources, and has been shown to have beneficial effects on serum lipid concentrations. The objective of this study was to investigate the effects of a policosanol , subject to the Cambridge Core terms of use, available at supplement (Octa-60) on lipid profiles of hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Nineteen hypercholes- terolaemic and familial hypercholesterolaemic subjects completed this randomised, placebo-controlled, double-blind study. The subjects received either a daily dose of 20 mg policosanol or placebo for 12 weeks. After a wash-out period of 4 weeks, the interventions were crossed over. Lipid levels were measured at baseline and at the end of each intervention period. No significant differences in total cholesterol and LDL-cholesterol from baseline to end or between policosanol and placebo were seen in the hypercholesterolaemic or familial hypercholesterolaemic groups. There were small reductions in total cholesterol and LDL-cholesterol from baseline to end in the hypercholesterolaemic group, but these changes did not differ significantly from the changes with the placebo, indicating that the observed decrease in cholesterol in the policosanol group was not due to the specific effect of policosanol treatment.
    [Show full text]
  • Category Approaches, Read-Across, (Q)SAR Technical Report No
    Category approaches, Read-across, (Q)SAR Technical Report No. 116 EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS Category approaches, Read-across, (Q)SAR Technical Report No. 116 Brussels, November 2012 ISSN-0773-8072-116 (print) ISSN-2079-1526-116 (online) Category approaches, Read-across, (Q)SAR ECETOC Technical Report No. 116 © Copyright – ECETOC AISBL European Centre for Ecotoxicology and Toxicology of Chemicals 2 Avenue E. Van Nieuwenhuyse (Bte 8), B-1160 Brussels, Belgium. All rights reserved. No part of this publication may be reproduced, copied, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder. Applications to reproduce, store, copy or translate should be made to the Secretary General. ECETOC welcomes such applications. Reference to the document, its title and summary may be copied or abstracted in data retrieval systems without subsequent reference. The content of this document has been prepared and reviewed by experts on behalf of ECETOC with all possible care and from the available scientific information. It is provided for information only. ECETOC cannot accept any responsibility or liability and does not provide a warranty for any use or interpretation of the material contained in the publication. ECETOC TR No. 116 Category approaches, Read-across, (Q)SAR Category approaches, Read-across, (Q)SAR TABLE OF CONTENTS SUMMARY 1 1. INTRODUCTION 3 1.1 Terms of reference 4 1.2 Scope 5 1.3 Roadmap of the report 6 2. DEFINITIONS FOR NON-TESTING APPROACHES 8 2.1 Data gap filling 9 2.1.1 Read-across 9 2.1.2 Trend analysis and computational methods based on internal models 13 2.1.3 External (Q)SAR models and expert systems 14 3.
    [Show full text]
  • Bristol-Myers Squibb Company
    Bristol-Myers Squibb Company Rx only COUMADIN TABLETS Anticoagulant (Warfarin Sodium Tablets, USP) Crystalline COUMADIN FOR INJECTION (Warfarin Sodium for Injection, USP) DESCRIPTION COUMADIN (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4- hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. The crystallization of warfarin sodium virtually eliminates trace impurities present in amorphous warfarin. Its empirical formula is C19H15NaO4, and its structural formula may be represented by the following: O O H C ONa CH2COCH3 Crystalline warfarin sodium occurs as a white, odorless, crystalline powder, is discolored by light and is very soluble in water; freely soluble in alcohol; very slightly soluble in chloroform and in ether. COUMADIN Tablets for oral use also contain: All strengths: Lactose, starch and magnesium stearate 1 mg: D&C Red No. 6 Barium Lake 2 mg: FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 2-1/2 mg: D&C Yellow No. 10 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake 3 mg: FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 4 mg: FD&C Blue No. 1 Aluminum Lake 5 mg: FD&C Yellow No. 6 Aluminum Lake 1 Approved 1.0 proposed.pdf Page 001 Bristol-Myers Squibb Company 6 mg: FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake 7-1/2 mg: D&C Yellow No.
    [Show full text]
  • Student Number: 201477310
    COPYRIGHT AND CITATION CONSIDERATIONS FOR THIS THESIS/ DISSERTATION o Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. o NonCommercial — You may not use the material for commercial purposes. o ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. How to cite this thesis Surname, Initial(s). (2012) Title of the thesis or dissertation. PhD. (Chemistry)/ M.Sc. (Physics)/ M.A. (Philosophy)/M.Com. (Finance) etc. [Unpublished]: University of Johannesburg. Retrieved from: https://ujcontent.uj.ac.za/vital/access/manager/Index?site_name=Research%20Output (Accessed: Date). Metabolomics, Physicochemical Properties and Mycotoxin Reduction of Whole Grain Ting (a Southern African fermented food) Produced via Natural and Lactic acid bacteria (LAB) fermentation A Thesis submitted to the Faculty of Science, University of Johannesburg, South Africa In partial fulfilment of the requirement for the award of a Doctoral Degree in Food Technology By OLUWAFEMI AYODEJI ADEBO STUDENT NUMBER: 201477310 Supervisor : Dr. E. Kayitesi Co-supervisor: Prof. P. B. Njobeh October 2018 EXECUTIVE SUMMARY Drought and challenges related to climate change are some of the issues facing sub-Saharan Africa countries, with dire consequences on agriculture and food security. Due to this prevailing situation, drought and climate resistant crops like sorghum (Sorghum bicolor (L) Moench) can adequately contribute to food security. The versatility and importance of sorghum is well reflected in its use as a major food source for millions of people in sub-Saharan Africa.
    [Show full text]
  • Muhammed Majeed, Ph.D. & Lakshmi Prakash
    POLICOSANOL NATURALLY HEALTHFUL FROM THE INSIDE & OUT …from sugarcane wax presented by Authors: Muhammed Majeed, Ph.D. & Lakshmi Prakash, Ph.D. [email protected] www.sabinsa.com www.sabinsacosmetics.com WHAT IS POLICOSANOL? Policosanol is a natural mixture of higher aliphatic alcohols, found in plant waxes. Sugarcane wax is a common commercial source. The components of policosanol include 1-octacosanol, 1- dotriacontanol, 1-tetracosanol, 1-tetratria-contanol, 1-hexacosanol, 1- heptacosanol and 1-nonacosanol. This mixture of alcohols is clinically proven to be effective in maintaining normal cholesterol levels. Preclinical and clinical studies published in scientific literature reveal that Policosanol beneficially influences cholesterol metabolism (Gouni-Berthold, 2002; Menindez, 1994; Menindez, 1996). The healthful role of policosanol in cosmetic and personal care formulations is described in a recent US Patent (Majeed, et al., 2007) that details a solvent free extraction process for policosanol from natural sources. This patent describes an innovative process for producing commercial quantities of policosanol containing 70 to 95 percent C28 fatty alcohol (Octacosanol) along with other lower chain length fatty alcohols, for use in cosmeceutical applications designed to control sebum, inhibit the growth of microbes and promote hydration and softening of the skin. Moreover, the process of extraction is solvent free so that it has low environmental impact. © 2007 Sabinsa Corporation 2 of 13 CARDIOVASCULAR BENEFITS Effects on cholesterol metabolism (Gouni-Berthold, et al.; 2002) and antioxidant benefits that prevent the oxidation of LDL-cholesterol, are reported to be responsible for the healthful effects of policosanol (Menindez, et al., 2000). In clinical studies, `Policosanol was shown to be effective in lowering both total cholesterol and low-density lipoprotein (LDL) cholesterol, the 'bad' cholesterol and to increase levels of the 'good' type of cholesterol, high-density lipoprotein (HDL) cholesterol (Gouni- Berthold, et al.; 2002).
    [Show full text]
  • Viscous Soluble Fiber Combined with Phytosterols and Policosanol Reduces Ldl-Cholesterol and Increases Hdl-Cholesterol in Hypercholesterolemia
    Current Topics in Nutraceutical Research Vol. 5, No. 1, pp. 1-6, 2007 ISSN 1540-7535 print, Copyright © 2006 by New Century Health Publishers, LLC www.newcenturyhealthpublishers.com All rights of reproduction in any form reserved VISCOUS SOLUBLE FIBER COMBINED WITH PHYTOSTEROLS AND POLICOSANOL REDUCES LDL-CHOLESTEROL AND INCREASES HDL-CHOLESTEROL IN HYPERCHOLESTEROLEMIA Peter J.E. Verdegem Research and Development Department, Unicity International, 1201 North 800 East, Orem, UT 84097 [Manuscript Received December 1, 2006; Manuscript Accepted: March 1, 2007] ABSTRACT: This pilot study investigates the efficacy of a successful, followed by pharmaceutical interventions, such as combination of nutraceuticals in improving lipid levels. The statins, fibrates, and bile-acid sequestrants. In the last decades, tested product combines viscous soluble fiber with phytosterols, an increasing number of non-pharmaceutical intervention policosanol, and an extract of Chrysanthemum morifolium. All therapies has been developed, and tested in randomized four ingredients have been shown to have cholesterol-lowering clinical trials. Examples are viscous soluble fiber, (Anderson et potential, but all through different biological mechanisms. The al. , 1999; Anderson et al. , 2000; Chandalia, 2000; Jenkins test product is the first to combine these four cholesterol-lowering et al. , 2002; Knopp et al. , 1999; Sprecher and Pearce, 2002) mechanisms in one product. Twenty-five subjects completed an phytosterols, and phytostanols, (Jenkins et al. , 2005; 8-week open label study design. The product was taken twice McPherson et al. , 2005; Plat and Mensink, 2005; Thompson, daily before the main meals. Fasting lipid panels were measured 2005; von Bergmann et al. , 2005) and policosanol. (Castano at baseline, 4, and 8 weeks.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrCOUMADIN* Warfarin Sodium Tablets, Bristol-Myers Squibb Std., (crystalline) 1, 2, 2.5, 3, 4, 5, 6 and 10 mg Anticoagulant Bristol-Myers Squibb Canada Date of Revision: Montreal, Canada. 10 March 2011 *TM of Bristol-Myers Squibb Pharma Company used under licence by Bristol-Myers Squibb Canada Control No.: 145303 1 PRODUCT MONOGRAPH PrCOUMADIN* Warfarin Sodium Tablets, Bristol-Myers Squibb Std., (crystalline) 1, 2, 2.5, 3, 4, 5, 6 and 10 mg THERAPEUTIC CLASSIFICATION Anticoagulant ACTION AND CLINICAL PHARMACOLOGY COUMADIN (warfarin sodium) and other coumarin anticoagulants act by inhibiting the synthesis of Vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. Half-lives of these clotting factors are as follows: Factor II - 60 hours, VII - 4-6 hours, IX - 24 hours, and X - 48-72 hours. The half-lives of proteins C and S are approximately 8 hours and 30 hours, respectively. The resultant in vivo effect is a sequential depression of Factors VII, IX, X and II. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of g- carboxyglutamic acid residues in the proteins which are essential for biological activity. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.
    [Show full text]
  • Pharmacy Program and Drug Formulary
    Pharmacy Program and Drug Formulary Secure Horizons Group Retiree Medicare Advantage Plan n Pharmacy Program Description n Platinum Plus Enhanced Formulary California Benefits Effective January 1, 2006 Table of Contents Your Secure Horizons Group Retiree Medicare Advantage Plan Prescription Drug Benefit........................................................................................................ iii Secure Horizons Pharmacy Program Definitions .................................................................... iii What Is the Platinum Plus Enhanced Formulary? ....................................................................iv Where to Have Your Prescriptions Filled .................................................................................iv Preferred and Non-Preferred Network Pharmacies .................................................................iv Network Preferred Pharmacy Locations ..................................................................................iv How to Fill a Prescription at a Network Pharmacy ...................................................................v Mail Service Pharmacy ..............................................................................................................v Secure Horizons Group Retiree Medicare Advantage Plan Offers a Two-Part Prescription Drug Benefit ..........................................................................vii Part 1 – Medicare Part D Prescription Drug Coverage ...................................................vii How Your Medicare
    [Show full text]
  • Sorghum: Variability of Nutrients and Bioactive Compounds and Their Heat Processing Stability
    LEANDRO DE MORAIS CARDOSO SORGHUM: VARIABILITY OF NUTRIENTS AND BIOACTIVE COMPOUNDS AND THEIR HEAT PROCESSING STABILITY Tese apresentada à Universidade Federal de Viçosa, como parte das exigências do Programa de Pós- Graduação em Ciência da Nutrição, para obtenção do título de Doctor Scientiae. VIÇOSA MINAS GERAIS - BRASIL 2014 i FichaCatalografica :: Fichacatalografica https://www3.dti.ufv.br/bbt/ficha/cadastrarficha/visua... Ficha catalográfica preparada pela Biblioteca Central da Universidade Federal de Viçosa - Câmpus Viçosa T Cardoso, Leandro de Morais, 1984- C268s Sorghum : variability of nutrients and bioactive 2014 compounds and their heat processing stability / Leandro de Morais Cardoso. - Viçosa, MG, 2014. xi, 112f. : il. (algumas color.) ; 29 cm. Orientador : Helena Maria Pinheiro Sant Ana. Tese (doutorado) - Universidade Federal de Viçosa. Inclui bibliografia. 1. Sorgo - Nutrientes. 2. Antioxidantes. 3. Flavonóides. 4. Carotenóides. 5. Vitamina E. I. Universidade Federal de Viçosa. Departamento de Nutrição e Saúde. Programa de Pós-graduação em Ciência da Nutrição. II. Título. CDD 22. ed. 633.62 2 de 3 07-03-2016 14:04 LEANDRO DE MORAIS CARDOSO SORGHUM: VARIABILITY OF NUTRIENTS AND BIOACTIVE COMPOUNDS AND THEIR HEAT PROCESSING STABILITY Tese apresentada à Universidade Federal de Viçosa, como parte das exigências do Programa de Pós- Graduação em Ciência da Nutrição, para obtenção do título de Doctor Scientiae. APROVADA: 25 de novembro de 2014. Hércia Stampini Duarte Martino Ana Vládia Bandeira Moreira (Coorientadora) Mônica Ribeiro Pirozi Valéria Aparecida Vieira Queiroz Helena Maria Pinheiro Sant’Ana (Orientadora) Dedico aos meus pais Maria e Antônio Paulo, às minhas irmãs Graciliane, Simone e Paloma e à minha namorada Soraia. AGRADECIMENTOS À Universidade Federal de Viçosa e ao Departamento de Nutrição e Saúde (DNS) pela oportunidade de realização do doutorado.
    [Show full text]
  • Helping Patients Achieve a Cholesterol Level Below 150 Mg/Dl Without Drugs
    Dynamic Chiropractic – April 9, 2007, Vol. 25, Issue 08 Helping Patients Achieve a Cholesterol Level Below 150 mg/dL Without Drugs An Important Objective in the Prevention of Cardiovascular Disease By James P. Meschino, DC, MS In recent years, medical practitioners have increasingly relied on statin drugs (HMG CoA reductase inhibitors), such as atorvastatin, lovastatin, fluvastatin, pravastatin, and rosuvastin, as a primary method to reduce high cholesterol. Statin drugs primarily work by blocking the production of cholesterol within the liver. These drugs have been shown to reduce total cholesterol levels by approximately 20 percent to 40 percent and reduce LDL cholesterol by a reported 27 percent to 55 percent. Statin drugs also have a modest effect on raising HDL and lowering triglyceride blood levels. 7 Overall, clinical studies have suggested that statin drugs reduce the risk of heart attack by approximately 30 percent over five years of treatment. 3,10,14,15,19,22,23 Drug companies indicate that the incidence of significant side effects associated with statin drugs is low: approximately 1 percent to 2 percent for serious muscle damage and liver dysfunction (usually represented as an increase in liver enzyme laboratory tests). 7 However, some physicians who prescribe these drugs indicate that side effects are much more common. A survey by a prominent American cardiologist suggests muscle aches and weakness occur in approximately 30 percent of patients who take statins. The survey further suggested patients who take a statin drug often develop annoying, sometimes incapacitating muscle aches and weakness that abruptly stop when they discontinue use of the drug, and return when drug use is resumed.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,141,611 B2 Gamble Et Al
    US007 141611B2 (12) United States Patent (10) Patent No.: US 7,141,611 B2 Gamble et al. (45) Date of Patent: *Nov. 28, 2006 (54) HIGH MOLECULAR WEIGHT PRIMARY C07C 29/76 (2006.01) ALPHATIC ALCOHOLS OBTANED FROM C07C 29/28 (2006.01) NATURAL PRODUCTS AND USES THEREOF CD7C 29/86 (2006.01) (75) Inventors: William R. Gamble, Longmont, CO (52) U.S. Cl. ...................... 514/724; 514/164:568/840; (US); Zhengjie Liu, Superior, CO 568/913:568/918 (US); David T. Bailey, Boulder, CO (58) Field of Classification Search ................ 514/164, (US); Pedro P. Perez, Hialeah, FL 514/724; 568/840,913, 918 (US); Dean P. Stull, Longmont, CO See application file for complete search history. (US); Steven L. Richheimer, Westminster, CO (US); Rebecca L. (56) References Cited Nichols, Broomfield, CO (US); Rod U.S. PATENT DOCUMENTS Lenoble, Westminster, CO (US) 5,663,156 A * 9/1997 Granja et al. ............... 514, 164 (73) Assignee: Wyeth, Madison, NJ (US) 6,235,795 B1* 5/2001 Hernandez et al. ......... 514,724 (*) Notice: Subject to any disclaimer, the term of this 6,423,697 B1 * 7/2002 Friedman .................... 514, 164 patent is extended or adjusted under 35 6,596,776 B1* 7/2003 Gamble et al. ............. 514,724 U.S.C. 154(b) by 0 days. * cited by examiner This patent is Subject to a terminal dis claimer. Primary Examiner Peter O'Sullivan (74) Attorney, Agent, or Firm Hogan & Hartson, LLP (21) Appl. No.: 10/622,249 (57) ABSTRACT (22) Filed: Jul.18, 2003 This invention provides an isolated mixture of higher (65) Prior Publication Data molecular weight primary aliphatic alcohols having 20, 22.
    [Show full text]
  • Advances in Fractionation and Analysis of Milk Carbohydrates
    DOI: 10.5772/intechopen.76312 ProvisionalChapter chapter 7 Advances in Fractionation and Analysis of Milk Carbohydrates VeenaVeena NagarajNagaraj,, Neelam Upadhyay,Neelam Upadhyay, Battula Surendra Nath and Ashish Kumar SinghAshish Kumar Singh Additional information is available at the end of the chapter http://dx.doi.org/10.5772/intechopen.76312 Abstract Lactose is a principal component of the milk obtained from the mammals. Milk also con- tains several other sugars such as monosaccharides and oligosaccharides in low concentra- tions. Lactose has reactive functional groups and can be converted to valuable food-grade derivatives for commercial applications through chemical and/or enzymatic reactions. Physical and chemical properties of carbohydrates determine the methods that can be used for their fractionation and purification. In this chapter, the advanced extraction tech- niques for fractionation and analytical methodologies applied for the determination of different carbohydrates of milk (lactose, lactulose, and oligosaccharides) are summarized. The main aim of this contribution is to provide the reader with a broad view on the recent fractionation and analytical techniques employed for the analysis of carbohydrates in dairy foods and their applications in food and pharmaceutical industry. Keywords: lactose, fractionation, purification, analytical techniques, applications 1. Introduction Lactose is the principal carbohydrate present in milk obtained from all mammalian spe- cies, such as cow, buffalo, goat, and sheep. The lactose content in milk is relatively constant, although it varies among different dairy products. Lactose is a disaccharide composed of glucose and galactose molecules linked through β(1–4) glycosidic bond and is synthesized in the mammary gland. Small amounts of free glucose and galactose may also be present [1].
    [Show full text]